Formulation and evaluation of norfloxacin suspension with β-cyclodextrin complexation

International Journal of Pharmaceutical Sciences Review and Research

Volumn 9, Issue 1, 2011, Pages 173-177

  Panda, Madhulita ^a   Patro, Ganesh ^b   Malpani, Amol ^c   Bhanoji Rao, M E ^c  

^a A P C Ray Memorial Cancer Chemotherapeutic Research Unit   (India)

^b Sri Venkateswara College of Pharmacy   (India)

^c ROLAND INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

cyclodextrin (CDs); Kneading; Norfloxacin; Sodium carboxy methyl cellulose (sodium CMC); Stability

Indexed keywords

BETA CYCLODEXTRIN; NORFLOXACIN;

ARTICLE; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG STABILITY; PARTICLE SIZE; PH MEASUREMENT; SEDIMENTATION RATE; SUSPENSION; TEMPERATURE SENSITIVITY; VISCOSITY;

EID: 79960614499     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Prapaporn B, Narubodee P, Suthimaln I, The formulation development and stability study of norfloxacin suspension, Thammasat Int J Sci Tech, 7, 2002, 1-4.
2. Murakawa GJ and Sable D, Quinolones in Dermatology, Clinical Dermatol, 21(1), 2003, 56-63.
3. Nangia A, Lam F, Hung CT, A stability study of aqueous solution of norfloxacin, Drug Dev Ind Pharm, 5, 1991, 681-94.
4. Sutar B, Bukovec N, Bukovec P, Polymorphism and stability of norfloxacin (1-ethyl-6-fluoro-1, 4-dihydro-4-oxo-7-(1-piperazinil)-3-quinolinocarboxylic acid, J thermal Ana, 40, 1993, 475-481.
5. Rathore YKS, Chatterjee PK, Mathur S, Sunderlal C, Sethi PD, Indian Drugs, 27, 1990, 215-217.
6. Florey K, Analytical Profiles of Drug Substances, Academic Press Inc, New York, 20, 1991, 557-600.
7. Kuchekar BS, Pattan SR, Godge RK, Formulation and evaluation of norfloxacin dispersible tablets using natural substances as disintegrants, J chem and pharm res, 1, 2009, 336-341.
8. Loftsson T, Guommundsdottir J, SigurjonsdottirJF, Sigursson HH, et al, Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray, Int J Pharm., 212, 2001, 29-40.
9. Rajendrakumar K, Pralhad T, Madhusudan S, Comparative study on co-ground products of rofecoxib with betacyclodextrin and its sulfobutyl ether-7 derivative in solution and in the solid state, J Incl Phenom Macro Chem, 49, 2004, 259-266.
10. Bekers O, Uijtendal EV, Beijnen JH, Bult A, et al, Cyclodextrins in pharmaceutical field, Drug Dev Ind Pharm, 17, 1991, 1503-1549.
11. Higuchi T, Connors KA, Phase solubility techniques, In: Reilly CN, ed. Advances in analytical chemistry instrumentation, New York, NY Interscien, 4, 1965, 117-212.
12. Paradkar A, Ambike AA, Jadhav BK, Characterization of curcumin-PVP solid dispersion obtained by spray drying, Int J Pharm, 271, 2004, 281-86.
13. Aftab M, Pralhad T, Enhancement of dissolution profile by solid dispersion (kneading) technology, AAPS Pharm Sci Tech, 7, 2006, 68-71.
14. Rowe RC, Sheskey PJ, Quinn ME, Hand Book of Pharmaceutical Excipients, sixth ed, Pharmaceutical Press, London, 2009, 118.
15. Liberman L, Rieger MM, Banker GS. A pharmaceutical dosage forms: Disperse systems, second ed, vol 1, Marcel Dekker Inc, New York, 1996, 291.
16. Aulton E, Pharmaceutics: The science of dosage form design, second ed, Churchill Livingstone, Edinburgh, 2002, 92.